UY33722A - Oxazolidinonas como moduladores de mglur5 - Google Patents

Oxazolidinonas como moduladores de mglur5

Info

Publication number
UY33722A
UY33722A UY0001033722A UY33722A UY33722A UY 33722 A UY33722 A UY 33722A UY 0001033722 A UY0001033722 A UY 0001033722A UY 33722 A UY33722 A UY 33722A UY 33722 A UY33722 A UY 33722A
Authority
UY
Uruguay
Prior art keywords
compounds
mglur5
oxazolidinones
modulators
agonists
Prior art date
Application number
UY0001033722A
Other languages
English (en)
Inventor
Andrew P Degnan
Huang Hong
Lawrence B Snyder
Yang Fukang
Kevin W Gillman
Michael F Parker
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY33722A publication Critical patent/UY33722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Por lo general, la descripción se refiere a compuestos de la fórmula 1, incluidas sus sales, así como a composiciones y métodos para el uso de Ios compuestos. Los compuestos son ligandos, agonistas y agonistas parciales del receptor mGluR5, y pueden ser útiles para el tratamiento de varios trastornos del sistema nervioso central.
UY0001033722A 2010-11-11 2011-11-11 Oxazolidinonas como moduladores de mglur5 UY33722A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41254110P 2010-11-11 2010-11-11

Publications (1)

Publication Number Publication Date
UY33722A true UY33722A (es) 2012-05-31

Family

ID=44999936

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033722A UY33722A (es) 2010-11-11 2011-11-11 Oxazolidinonas como moduladores de mglur5

Country Status (6)

Country Link
US (2) US8691821B2 (es)
EP (1) EP2638022B1 (es)
AR (1) AR083861A1 (es)
TW (1) TW201300369A (es)
UY (1) UY33722A (es)
WO (1) WO2012064603A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159738B (zh) * 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9790203B2 (en) * 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
EP2935237A1 (en) 2012-12-19 2015-10-28 Basf Se Substituted [1,2,4]triazole compounds and their use as fungicides
EP3055306A1 (en) * 2013-10-07 2016-08-17 Bristol-Myers Squibb Company Oxazolidinones as modulators of mglur5
CN107849006B (zh) 2015-06-03 2020-11-13 豪夫迈·罗氏有限公司 乙炔基衍生物
WO2023183428A1 (en) * 2022-03-22 2023-09-28 Allyx Therapeutics, Inc. Mglur5 modulating compounds, compositions, and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
ATE445399T1 (de) 2004-03-22 2009-10-15 Lilly Co Eli Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten
EP2244576A4 (en) * 2008-01-24 2011-06-08 Merck Sharp & Dohme 1,3-OXAZOLIDIN-2-ONE 3,5-SUBSTITUTED DERIVATIVES
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
EP3055306A1 (en) * 2013-10-07 2016-08-17 Bristol-Myers Squibb Company Oxazolidinones as modulators of mglur5

Also Published As

Publication number Publication date
WO2012064603A1 (en) 2012-05-18
TW201300369A (zh) 2013-01-01
EP2638022A1 (en) 2013-09-18
USRE49735E1 (en) 2023-11-28
US20120283264A1 (en) 2012-11-08
EP2638022B1 (en) 2014-12-24
AR083861A1 (es) 2013-03-27
US8691821B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP11011098A (es) Nuevas pirazol-4-n-alcoxicarboxamidas cómo microbicidas.
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY34649A (es) Compuestos heterobicíclicos
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
ECSP11011206A (es) Nuevos herbicidas.
CU20100159A7 (es) Compuestos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP109942A (es) Nuevos herbicidas
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY33722A (es) Oxazolidinonas como moduladores de mglur5
ECSP11011244A (es) Nuevos herbicidas.
ECSP11011218A (es) Herbicidas derivados de ciclopentanodiona.
PE20150966A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
ECSP11011133A (es) Nuevos herbicidas.
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina